Current Prospectives of Hormone Therapy in Breast Cancer Treatment
DOI:
https://doi.org/10.18311/jmmf/2023/34735Keywords:
Prospectives of hormone therapy, Breast Cancer, radiography, adenocarcinomas, angiosarcoma, biological therapy, chemotherapy, nano-technology, alopecia, thrombocytopenia, growth promoter proteinAbstract
Breast cancer, being a heterogeneous disease, includes an increased proliferation of breast cells, symptoms of which includelump in the breast, bloody discharge from the nipple area, and changes in the shape or texture of the nipple or breast. The types of breast cancer mainly encompass adenocarcinomas and angiosarcoma. The treatment of this disease depends on the stage. It incorporates local therapy like surgery and radiotherapy and systemic therapy like chemotherapy, hormone therapy, and biological therapy. Oestrogen and progesterone stimulate breast cells to grow and multiply. Hormone therapy is usually provided to patients whose tumors are hormone receptor-positive, meaning the hormones bind extensively to the surface receptors of the tumor cells and cause increased multiplication. Chemotherapy is usually more effective for patients with a high recurrence score, whereas hormone therapy is best used for low recurrence scores. Hormone therapy blocks the interaction of hormones with their specific receptors to prevent the development of tumors and is used in both adjuvant and metastatic cancers. In this our study focused on the course of action to treat breast cancer with hormone therapy is Selective estrogen receptor modulators such as Tamoxifen and raloxifene and other parameters with support of Nano-materials applications in preventing breast cancer.
Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
The American Cancer Society medical and editorial content team, 2017. Hormone therapy for breast cancer, 1-10.
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA et al. Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 Feb 10;37(5):423- 438.
Hormone Therapy in Breast Cancer Mãdãlina Drãgãnescu, Codruåa Carmocan “Prof. Dr. Al. Trestioreanu, Institute of Oncology, Bucharest, Romania. Chirurgia (2017) 112: 413-417 No. 4, July – August
Giacomo Barchiesi , Marco Mazzotta, Eriseld Krasniqi, Laura Pizzuti , Daniele Marinelli , Elisabetta Capomolla, Domenico Sergi, Antonella Amodio, Claa Natoli, Teresa Gamucci, Enrico Vizza, Paolo Marchetti, Claudio Botti, Giuseppe Sanguineti, Gennaro Ciliberto, Maddalena Barba, and Patrizia Vici. Published: 16 May 2020. Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. systematic review: comparative effectiveness of medications to reduce risk of breast cancer. Ann Intern Med. 2009, 151:703-715, W-226-2
Dalmau E, Armengol-Alonso A, Muñoz M, Seguí- Palmer MÁ. Breast. 2014 Dec;23(6):710-20. doi: 10.1016/ j.breast.2014.09.006. Epub 2014 Oct 11.
Alexander Tremont, DO, Jonathan Lu, MBBS, and John T. Cole, MD, 2021. Endocrine Therapy for Early Breast Cancer: Updated Review.
Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. systematic review: comparative effectiveness of medictions to reduce risk of breast cancer. Ann Intern Med. 2009, 151:703-715, W-226-2
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives - Giacomo Barchiesi , Marco Mazzotta, Eriseld Krasniqi, Laura Pizzuti, Daniele Marinelli, Elisabetta Capomolla, Domenico Sergi, Antonella Amodio, Claa Natoli, Teresa Gamucci, Enrico Vizza, Paolo Marchetti, Claudio Botti, Giuseppe Sanguineti, Gennaro Ciliberto, Maddalena Barba, and Patrizia Vici. Published: 16 May 2020.
Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, Kesharwani SS. A review of nano-technology-based approaches for breast cancer and triple-negative breast cancer. J Control Release. 2020 Oct 10; 326:628-647. doi: 10.1016/j.jconrel.2020.07.003. Epub 2020 Jul 10. PMID: 32653502.
Hussain Z, Khan JA, Murtaza S. Nano-technology: An Emerging Therapeutic Option for Breast Cancer. Crit Rev Eukaryot Gene Expr. 2018;28(2):163-175. doi: 10.1615/CritRevEukaryotGeneExpr.2018022771. PMID: 30055543.
Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices. 2009 Feb; 11(1):49-63. doi: 10.1007/ s10544-008-9209-0. PMID: 18663578.
Alaa T. Alshareeda, M.Z. Nur Khatijah, Batla S. Al- Sowayan, Nano-technology: A revolutionary approach to prevent breast cancer recurrence, Asian Journal of Surgery, 2022,
Lee JJ, Saiful Yazan L, Che Abdullah CA. A review on current nano-materials and their drug conjugate for targeted breast cancer treatment. Int J Nano-medicine. 2017 Mar 27;12:2373-2384. doi: 10.2147/IJN.S127329. PMID: 28392694; PMCID: PMC5376210.
Cui G, Wu J, Lin J, Liu W, Chen P, Yu M, Zhou D, Yao G. Graphene-based nano-materials for breast cancer treatment: promising therapeutic strategies. J Nanobiotechnology. 2021 Jul 15;19(1):211. doi: 10.1186/ s12951-021-00902-8. PMID: 34266419; PMCID: PMC8281664.
N A Saeed et al 2021 J. Phys.: Conf. Ser. 1853 012061. The applications of nano-medicine in the breast cancer therapy, Pg 1-10.
Márcia Rocha, Natalia Chaves and Sônia Báo, 2016. Nano-technology for breast cancer treatment.
Guirguis Celine, Olivia Ye, Sherilyn Wen, 2021. Nanotechnology: A therapeutic option for breast cancer.
Tang X, Loc WS, Dong C, Matters GL, Butler PJ, Kester M, Meyers C, Jiang Y, Adair JH. The use of nano-particulates to treat breast cancer. Nanomedicine (Lond). 2017 Oct;12(19):2367-2388. doi: 10.2217/nnm-2017-0202. Epub 2017 Sep 4. PMID: 28868970; PMCID: PMC5612024.